A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer

Astellas Pharma Global Development, Inc.

Overview

The purpose of this study is to investigate radiographic progression-free survival (PFS) of enzalutamide in chemotherapy-naïve patients with progressive metastatic castration-resistant prostate cancer who have symptomatic disease.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

EnzalutamideDRUG

oral

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * Progressive prostate cancer while on androgen deprivation therapy * Castrate testosterone level * Maintenance of surgical or medical castration for duration of study * Radiographically visible metastatic disease * Symptomatic from prostate cancer * Eastern Cooperative Oncology Group (ECOG) 0-2 * Life expectancy \>=6 months Exclusion Criteria: * Brain metastases or leptomeningeal disease * Prior cytotoxic chemotherapy for prostate cancer * Prior use of ketoconazole or abiraterone acetate or other investigational agent that blocks androgen synthesis or targets androgen receptor * History of seizure or condition that may predispose to seizure * History of loss of consciousness or transient ischemic attack within 12 months * Clinically significant cardiovascular disease

Outcomes

Primary Outcomes

Radiographic progression free survival (PFS)

Time from first dose on Day 1 to the first objective evidence of radiographic progression or death due to any cause (whichever occurs first). Radiographic disease progression is defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Prostate Cancer Clinical Trials Working Group 2 (PCWG2).

Time frame: 26 months

Secondary Outcomes

Overall survival

Time from first dose on Day 1 to death due to any cause

Time frame: 26 months

Time to PSA progression

Time from first dose on Day 1 to first observation of PSA progression

Time frame: 26 months

Change from baseline to last post baseline measurement Quality of life score using Functional Assessment of Cancer Therapy-Prostate (FACT-P)

The FACT-P quality of life questionnaire is a multi-dimensional, self-reported quality of life instrument specifically designed for use with prostate cancer patients

Time frame: Baseline and 26 months

Change from baseline to last post baseline measurement Quality of Life score using European Quality of Life 5-Domain Scale (EQ-5D)

EQ-5D is a standardized instrument for use as a measure of health outcome. It provides a simple descriptive profile and a single index value for health status and is designed for self-completion by respondents

Time frame: Baseline and 26 months

Change from baseline to last post baseline measurement Pain Assessments (Brief Pain Inventory - Short Form)

Brief Pain Inventory is a validated instrument that is a subject self-rating scale assessing level of pain, effect of the pain on activities of daily living, and analgesic use

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.